Completed PHASE2 INTERVENTIONAL NCT00109564

A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)

A Safety and Efficacy Study of TC-1734-112 in Subjects With Age Associated Memory Impairment (AAMI)

Sponsor: Targacept Inc.

Interventions ispronicline (nicotinic acetylcholine receptor agonist)

Updated 6 times since 2017 Last updated: Jul 17, 2008 Started: Jan 31, 2005 Completion: Oct 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Age-Related Memory Disorders, this trial is completed. The trial is conducted by Targacept Inc. and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Targacept Inc.

Data source: Targacept Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Decatur, United States , Denver, United States , Florence, United States , Fort Meyers, United States , Greensboro, United States , Mesa, United States , Minneapolis, United States , Peoria, United States , Philadelphia, United States , Saint Petersberg, United States and 5 more locations